( January 17, 2024, 2:07 PM EST) -- LOS ANGELES — A biotechnology company misled investors by suggesting that its COVID-19 vaccine was still relevant despite not having approval from the Food and Drug Administration to target the most common subvariant at the time, an investor says in a purported class complaint filed in the U.S. District Court for the Central District of California....